The purpose of this article is to explore the management of coexisting brain insult and acute lung injury to help guide clinicians in balancing what may appear to be competing goals. First, contemporary management of mechanically ventilated patients with either brain or lung injury diagnoses is reviewed, followed by a review of intracranial pressure and acute lung injury/acute respiratory distress syndrome. The article ends with a discussion of a literature review regarding possible treatment balance when the two conditions coexist.
T
he Centers for Disease Control and Prevention (Faul, Xu, Wald, & Coronado, 2010) report that 1.7 million people experience traumatic brain injury (TBI) annually. Reports indicate that 2%Y51% of people with TBI require intubation (Dunham et al., 2003) . Although the initial traumatic insult can lead to damage of the lung (i.e., contusion or rib fractures), many of these patients develop acute lung injury (ALI) unrelated to the initial traumatic insult. Whether the patient presents with TBI, subarachnoid hemorrhage, or ischemic stroke, several possible contributing factors can lead to the development of ALI. Some of the identified contributing factors include neurogenic pulmonary edema, aspiration, shock, crystalloid administration, induced arterial hypertension, or systemic inflammatory reaction (Contant, Valadka, Gopinath, Hannay, & Robertson, 2001; Eberhard et al., 2000; Holland et al., 2003; Mascia, 2009) . The management of a patient with a brain injury who develops ALI is challenging because of conflicting goals for the control of carbon dioxide levels in the two disease processes. The challenge facing the clinician in this situation is how to preserve optimal oxygenation in the lungs while protecting the damaged and vulnerable brain. This article highlights the issues clinicians face while trying to preserve optimal cerebral blood flow and protect the lungs in brain-injured patients with ALI or acute respiratory distress syndrome (ARDS). The purpose of this article is to explore the management of coexisting brain insult and ALI, including emerging data from animal models, to guide the clinician in balancing what may appear to be competing goals. First, contemporary management of mechanically ventilated patients with either brain or lung injury diagnoses is reviewed, followed by a review of intracranial pressure (ICP) and ALI/ARDS. The article concludes with a discussion of a literature review regarding possible treatment balance when the two conditions coexist.
Current Management Guidelines
The Guidelines for the Management of Severe Traumatic Brain Injury (Brain Trauma Foundation, 2007) contains recommendations for oxygenation targets. Surprisingly, the recommendation provides level III evidence concerning hypoxemia in the brain-injured patient because insufficient data are available to support a higher recommendation. The current recommendation is simply that hypoxia should be avoided (PaO 2 G 60 mm Hg or O 2 saturation G 90%). Recommendations on carbon dioxide levels for the brain-injured patient are to maintain normocapnia between 35 and 40 mm Hg. Hyperventilation as a temporizing measure to treat elevated intracranial hypertension is a level III recommendation (Brain Trauma Foundation, 2007) .
Guidelines for the management of ALI and the more severe ARDS center around reduced tidal volumes (6 ml/kg) and lower plateau pressures (G30 cm H 2 O) to increase oxygenation (Ventilation with lower tidal, 2000) . A potential consequence of this mode of ventilation is the development of hypercapnia because of insufficient exchange of carbon dioxide due to the lower tidal volumes. Hypercapnia is usually tolerated by patients with ALI/ARDS but becomes more problematic with the concurrent diagnosis of brain injury.
Exploring the Role of Carbon Dioxide in ICP and ALI/ARDS
Regardless of the type of brain injury experienced by a patient, a major goal of the clinician is to maintain normal cerebral perfusion pressure (CPP) and ICP to provide the injured brain with optimal oxygenation. The importance of managing CPP in the brain-injured patient is amplified when autoregulation is impaired. The clinician needs to recognize decrements in CPP and provide treatment quickly to maintain safe and effective levels of perfusion to the brain (Rangel-Castilla, Gopinath, & Robertson, 2008) . The challenge in braininjured patients is often the dramatic increases in ICP that lead to intracranial hypertension and decreased CPP. Intracranial hypertension can be caused by multiple sources. There can be an intracranial cause such as a brain tumor; trauma; intracerebral hemorrhage; hydrocephalus; and/or extracranial causes such as hypoxia, hypercarbia, posture, hyperpyrexia, seizures, or drugs (Rangel-Castilla et al., 2008) . The mechanisms by which each of the different causes of intracranial hypertension affects ICP are diverse. Hypercarbia's physiological explanation is that carbon dioxide combines with water in body fluids to form carbonic acid. The carbonic acid dissociates to form hydrogen ions that cause vasodilation of the cerebral vessels and cerebral volume expansion (Hall, 2011) .
Clinicians have used hyperventilation as a means to lower carbon dioxide in the blood, causing vasoconstriction of the cerebral vessels to lower ICP. Hyperventilation may be temporary, to reverse a transient increase in ICP, or sustained, such as with mechanical ventilation strategies of increased tidal volume or respiratory rate to achieve an arterial carbon dioxide level of 32Y34 mm Hg for persistent elevated ICP. Currently, this intervention is controversial and applied in the emergent treatment of intracranial hypertension (Brain Trauma Foundation, 2007; Rangel-Castilla et al., 2008) .
ALI and ARDS are distinct diagnoses with treatment guidelines specific to the diseases. The ARDS consensus statement (Bernard et al., 1994) The criteria for ARDS include all those of ALI except for the PaO 2 /FiO 2 ratio of e200 mm Hg (Bernard et al., 1994) . The pathophysiology of ALI/ARDS involves several stages and pathways. The beginning exudative stage with diffuse alveolar damage and pulmonary edema is followed by the proliferative phase in which interstitial and alveolar inflammation, fibrosis, and disordered healing occur (Lanken, 2005) . The result of these cellular changes is reduced lung compliance and severe hypoxia (Lanken, 2005) . Although there is believed to be many precipitating causes to developing ALI/ARDS, such as aspiration, pneumonia, sepsis, and others, all these causes follow a ''final common pathway'' that leads to lung tissue damage (Lanken, 2005) .
Historically, treatment of hypoxemia in patients with ALI/ARDS involved applying positive endexpiratory pressure (PEEP) and using large tidal volumes (10Y15 ml/kg) that led to higher peak and end-inspiratory pressures (Lanken, 2005) . The ultimate goals of this approach were to maintain arterial oxygen saturations (PaO 2 ) above 88%Y90% and keep arterial pH and carbon dioxide (PaCO 2 ) within normal limits (Brower, 2002; Lanken, 2005) . Then in 2000, a multicenter, randomized study conducted by the Acute Respiratory Distress Syndrome Network challenged the traditional ventilator management approach and found that ventilation with lower tidal volumes (6 ml/kg) and decreased peak pressures (30 cm H 2 O or less) resulted in decreased mortality for the treatment group (Ventilation with lower tidal, 2000). Treatment goals for ALI/ARDS then shifted to a lung protective strategy that no longer focused on maintaining arterial pH and PaCO 2 within normal limits but rather allowed for permissive hypercapnia (Brower, 2002; Lanken, 2005; Ventilation with lower tidal, 2000) .
Coexistence of Brain Injury and ALI/ARDS
A retrospective study conducted to look at the prevalence of ALI/ARDS in traumatic brain-injured patients found that the prevalence of ALI/ARDS increased from 2% in 1988 to 22% in 2008 (Rincon et al., 2012) .
Ongoing management of cerebral perfusion pressure (CPP) is critical in all brain-injured patients but is significantly more challenging in patients with acute lung injuries who must be supported with mechanical ventilation.
Although the increased prevalence may be because of better definitions (the publication of the ARDS consensus statement in 1994), the 28% mortality associated with ALI/ARDS after a TBI remains significant and relatively unchanged from 1988 (Rincon et al., 2012) . The exact mechanism for the development of pulmonary dysfunction in brain-injured patients is unclear. Historically, the blast injury theory was one explanation as to why brain-injured patients developed neurogenic pulmonary edema (Theodore & Robin, 1975) . This theory proposes that the sympathetic storm caused by elevations in ICP changes the intravascular pressure leading to endothelium damage and the escape of plasma into the alveoli (Mascia, 2009) . Recently a Double Hit Model has been developed to explain why pulmonary dysfunction is often seen in brain-injured patients. This model states that a systemic inflammatory environment is created by the initial insult to the brain. This initial hit includes a catecholamine storm and inflammatory reactions. This then primes the body to be more vulnerable to secondary insults such as infections, lung trauma from mechanical ventilation, and transfusions (Mascia, 2009) . Alternatively, ALI and ARDS can occur in the brain-injured patient because of primary lung damage (including preexisting disease), infection such as ventilator-associated pneumonia, and fluid therapy. Recent research suggests that the options available to the clinician in balancing competing goals for carbon dioxide management are not as limited as once thought and that some ventilation strategies might improve lung function while preserving brain tissue.
PEEP
The use of PEEP has been well studied in both braininjured patients and patients with ARDS. In ARDS, the alveoli collapse and become fluid filled. When PEEP is applied, partially collapsed alveoli are stented opened and recruited to provide improved oxygenation. However, PEEP also increases intrathoracic pressure with the potential to increase resistance to passive cerebral venous blood flow and cerebral spinal fluid outflow. Several studies have examined the effect of PEEP in brain-injured patients. Concerns over the effect of PEEP on ICP and CPP have been evaluated in several research studies. These studies support the practice of maintaining the PEEP below the patients' ICP (McGuire, Crossley, Richards, & Wong, 1997) and maintaining the mean arterial pressure at normal levels with either fluid or vasoactive drugs (Georgiadis, Schwarz, Baumgartner, Veltkamp, & Schwab, 2001; Muench et al., 2005) . A study performed by Mascia (2009) further evaluated the effect of PEEP on ICP in patients with ALI brain injury. Those patients found not to respond as recruiters to increased levels of PEEP experienced increases in PaCO 2 secondary to hyperinflation of the lungs that lead to a significant increase in ICP mediated by cerebral vasodilation (Mascia, 2009) . In those patients found to be recruiters after higher application of PEEP, there was no change in ICP but an improvement in oxygen saturation. Furthermore, researchers have found that PEEP can positively influence the brain tissue oxygen pressure in patients with brain injury and ALI (Nemer et al., 2011) . Researchers have shown that PEEP can lead to an improvement in oxygen saturation but can also affect CPP by way of hypercapnia, vasodilation, and alterations in mean arterial pressure. Although PEEP may be a potentially effective method of increasing oxygenation, its application requires careful selection and continuous invasive monitoring of patients.
Tracheal Gas Insufflation
Tracheal gas insufflation offers the potential to balance low tidal volumes with normocapnia. In this treatment, a catheter is placed above the carina, and a set flow of gas is introduced during the expiratory phase of positive pressure ventilation. The result is a reduction in anatomic dead space and carbon dioxide in the airways (Ravenscraft et al., 1993) . There is limited data related to the use of this therapy in brain-injured patients. One prospective study of seven patients with severe head trauma and ALI/ARDS found that tracheal gas insufflation resulted in decreased tidal volumes (from 9.1 to 7.2 ml/kg) while maintaining normocapnia (i.e., PaCO 2 of 35Y40 mm Hg; Martinez-Perez et al., 2004) . Other results included slight improvement in oxygenation and no significant changes in ICP (MartinezPerez et al., 2004) . These findings are consistent with outcomes from an earlier case report (Levy, Bollaert, Nace, & Larcan, 1995) . Although promising results, there are significant risks associated with the use of tracheal gas insufflation. This adjunctive treatment can cause an increase in auto-PEEP related to increased expiratory flow resistance, which can result in increased intrathorasic pressure and changes in ICP (MartinezPerez et al., 2004) . Other potential complications include tracheal erosion, oxygen toxicity, blood clot formation, and mucous and bronchial damage (Lanken, 2005; Levy et al., 1995) . This intervention requires continuous monitoring and the use of additional specialized equipment. The lack of higher quality evidence regarding tracheal gas insufflation in brain-injured patients requires cautious use of this intervention. Use should be limited to those centers with experience in its use in patients with ARDS and to clinical trials. 
High-Frequency Oscillatory Ventilation
The neonatal intensive care unit (ICU) introduced highfrequency oscillatory ventilation (HFOV) in the 1960s. Over the past decade, it has been identified as a type of rescue therapy for adults with ARDS. This mode of ventilation provides small tidal volumes and high mean airway pressures that prevent both collapse and overdistention of the alveoli, a key goal in ARDS treatment (Chan, Stewart, & Mehta, 2007) . Concern with using HFOV in a brain-injured patient centers around changes in the partial pressure of carbon dioxide in the blood and blood pressure changes that ultimately may affect ICP and CPP (Young & Andrews, 2011) . Several studies have explored the effects of HFOV in patients with brain injuries and ALI. Unfortunately, most human data collection has been conducted in small retrospective case series (Bennett, Graffagnino, Borel, & James, 2007; David et al., 2005) . The only prospective trials researching HFOV to treat ALI with brain injury were conducted in animal models (David et al., 2006; Heuer et al., 2011) . Interestingly, these data do provide limited support that HFOV may be an effective ventilation strategy in this patient population. When evaluating the effect of HFOV on cerebral hemodynamics, no study found uncontrollable changes in ICP or CPP during HFOV (Bennett et al., 2007; David et al., 2005) . A single systematic review of limited data concluded that the current evidence ''should at best be considered as hypothesis generating rather than for drawing evidence-based conclusions'' (Young & Andrews, 2011). Although this review was unable to draw any conclusions about a mortality benefit in this subpopulation of patients with ALI and TBI, larger studies about ALI/ARDS have failed to show a mortality benefit with this mode of ventilation compared with traditional modes (Wunsch & Mapstone, 2004; Wunsch, Mapstone, & Takala, 2005; Young & Andrews, 2011) . Ultimately, this mode of ventilation may be unrealistic for hospitals that do not have access to this specialized equipment. Furthermore, currently, no data provide strong support for its routine use. In those institutions with access to this mode of ventilation, use must be limited to patients with continuous invasive monitoring equipment including ICP, mean arterial pressure, PaCO 2 , and SpO 2 and specially trained providers that can respond quickly to changing patient hemodynamics and only after thorough conversations with patient's family members.
Nitric Oxide
As a potent dilator of the pulmonary blood vessels, nitric oxide (NO) has been shown to improve oxygenation in patients with ARDS (Afshari, Brok, Moller, & Wetterslev, 2011). Several case reports have shown a rapid correction of hypoxemia and improvement in ICP after the administration of NO in brain-injured patients with ALI (Gritti et al., 2012; Papadimos, Medhkour, & Yermal, 2009; Vanhoonacker, Roeseler, & Hantson, 2012) . These case reports have only included data for three patients between 20 and 37 years. All patients were successfully weaned from mechanical ventilation and experienced no complications related to NO use, but two patients continued to experience severe cognitive deficits after discharge (Papadimos et al., 2009; Vanhoonacker et al., 2012) . Several interesting hypothesizes have been generated to explain the potential beneficial effect of NO, not only locally in the lungs but also distally with hippocampal preservation and influences on inflammation in TBI patients with ARDS (Papadimos et al., 2009) . Drawing from previous research in ARDS and NO, NO has the potential to harm the kidneys and the risk of methemoglobin, in addition to a tremendous economic cost (Afshari et al., 2011; Lanken, 2005) . A recently completed systematic review that included both adults and children found no significant effect on mortality, duration of ventilation, ventilator-free days, or length of ICU stay (Afshari et al., 2011) . Whereas researchers continue to investigate the molecular interaction of NO in these patients and conduct randomized studies with large populations, the clinician remains without strong evidence to support the routine use of NO. Therefore, the utility of NO needs further investigation in brainand lung-injured patients, and its routine use cannot be recommended at this time.
Prostacyclin Infusion
As a member of the prostaglandin family, prostacyclin is released by endothelial cells causing vasodilation and inhibition of platelets (Lowson, 2002) . Inhaled and intravenous prostacyclin (PGI 2 ) have been used in pulmonary hypertension, ARDS, and peripheral vascular disease because of its vasodilatory properties and its interesting ability to stimulate NO production (Lowson, 2002) . In addition, research has also shown a potential benefit of prostacyclin in reducing neuronal cell death after a brain injury (Bentzer, Mattiasson, McIntosh, Wieloch, & Grande, 2001) . Researchers have also shown an improvement in lactate levels around the injured part of the brain, increased glucose, and improved jugular bulb blood oxygenation with low-dose (below those recommended for ARDS) prostacyclin administration (Grande, Moller, Nordstrom, & Ungerstedt, 2000) . Potential adverse effects with its use include hypotension and bleeding owing to its vasodilating and platelet inhibiting properties. There has only been one case report of a single patient published in the literature regarding prostacyclin use in patients with TBI and ALI/ARDS. Although the authors noted an improvement in brain tissue oxygenation, there was a slight increase in ICP without a significant effect on CPP (Q60 mm Hg) during prostacyclin initiation (Stiefel, Zaghloul, Bloom, Gracias, & LeRoux, 2007) . After discontinuation of prostacyclin, the patient experienced an elevation in ICP, evolution of the contusion, and cerebral edema requiring a hemicraniectomy. Although no direct causation can be drawn from this event, this finding must raise serious concerns with prostacyclin use. This case report did use higher doses than those used in the prior mentioned trials that did not report any hemorrhagic complications. Until further research is conducted that examines the safety of prostacyclin in this subgroup of patients, the potential risks seem to outweigh the benefits and use cannot be recommended outside of controlled trials with informed patient/ family consent.
Extracorporeal Membrane Oxygenation
Extracorporeal membrane oxygenation (ECMO) has recently been investigated in the treatment of braininjured patients with ARDS (Lanken, 2005) . ECMO can reduce hypercarbia, improve oxygenation, and allow the injured lung to rest or recover. The use of ECMO involves either veno-arterial or veno-venous cannulation of the femoral or jugular vessels. Complications include neurological injury, sepsis related to catheters, bleeding related to heparin administration, pneumothorax, oliguria, and cardiovascular and gastrointestinal complications (Mateen et al., 2011; Rodriguez, 2013) . Most importantly, the clinician using ECMO must have special resources (i.e., ECMO devices, trained staff, and ability to provide sustained 1:1 or 2:1 care) and collaborate closely with cardiothoracic colleagues to provide this treatment option. Until recently, the mortality benefit of ECMO was questioned, but new research may be offering new insights into the potential benefit ECMO offers patients (Australia and New Zealand Extracorporeal Membrane Oxygenation Influenza Investigators et al., 2009; Peek et al., 2009 ). Only two reports have been published examining ECMO in brain-injured patients with ALI/ARDS. The first retrospective analysis examined five patients with TBI and ARDS who were connected to a pumpless extracorporeal lung assist system. The results were reductions in ICP and hypercapnia and improvement in oxygenation for three patients (Bein, Scherer, Philipp, Weber, & Woertgen, 2005 ). An additional case report documented the use of two oxygenators during ECMO in a patient with TBI and ARDS. The ECMO resulted in reduced CO 2 and improved oxygen saturation. After 7 days on ECMO and additional days of ICU and hospital care, the patient was discharged with normal neurological status (Leloup, Roze, Calderon, & Ouattara, 2011) . These two small studies may highlight a potentially beneficial intervention for these patients. Additional study of the patient with both brain and lung injury and ECMO as an intervention is needed. Especially important is additional information about optimal sites for cannulation, effects of heparin administration, and neurological outcomes.
Hypercapnia
Perhaps, the most intriguing research challenges historical dogma about the effect of carbon dioxide on the injured brain. In a randomized control study conducted in rats selected to receive permissive hypercarbia after a transient global cerebral ischemic injury, mild-to-moderate hypercapnia (PaCO 2 of 60Y100 mm Hg) was found to be neuroprotective after transient global cerebral ischemia-reperfusion injury (Zhou et al., 2010) . Zhou and colleagues showed that mild-to-moderate hypercapnia (80Y100 mm Hg) was associated with fewer histopathological changes and reduced cerebral apoptosis, which lead to better neurological deficit scores when compared with other levels of PaCO 2 (60Y80 or 100Y120 mm Hg). The authors theorize that mild-to-moderate hypercarbia interferes with apoptosisregulating proteins, brain oxygen tension, and interaction with neurotransmitters, thus decreasing cell death and increasing neurological deficits scores (Zhou et al., 2010) . The benefits of hypercapnia were not unlimited; in fact, severe hypercapnia (PaCO 2 of 100Y120 mm Hg) increased brain injury (Zhou et al., 2010) . Although examined in animal models, few studies have examined the effects of permissive hypercapnia in brain-injured patients.
In a small retrospective study conducted in 12 patients with both subarachnoid hemorrhage and ARDS, a lung protective strategy (i.e., tidal volume of 5Y8 ml/kg and PEEP of 10Y15 cm H 2 O) was employed with resulting hypercapnia (pCO 2 of 50Y60 mm Hg; Petridis et al., 2010) . The researchers showed that, despite hypercapnia, there was no increase in intracerebral pressure. Findings from prior experimental studies in baboons with ischemic injuries indicated that the major cerebral arteries and the intracortical arteries of the brain constrict rather than dilate in the presence of hypercapnia, and the current authors use these data to support their findings (Mchedlishvili, Ormotsadze, Nikolaishvili, & Baramidze, 1967) .
Although the results of these studies are thought provoking, caution needs to be used when applying these results in clinical practice. It is important to note in the Petridis et al. study that all the patients had subarachnoid hemorrhages with intracranial monitoring devices and a ventriculostomy that was draining cerebral spinal fluid (Petridis et al., 2010) . Also, the study was not randomized, and the sample size was small. As an editorial article written by Reinges highlights, ''the treatment reported in the paper by Petridis and colleaguesIcannot generally be recommended until studies with a better design, especially controlled, randomized studies, have confirmed the results'' (Reinges, 2010) . Specific questions to be addressed include as follows: Is the result reproducible in different and or larger patient subtypes (i.e., ischemic injuries), and what is the interaction of hypercapnia and ICP? Until better-designed randomized, controlled studies with larger populations conducted in humans are performed, the clinician cannot feel comfortable allowing their patients to experience uncontrolled hypercapnia based on the current data.
Conclusion
The management of ventilation in patients with both brain and lung injury remains challenging. Perhaps the best evidence gained from this review is support of preventive measures in intubated patients such as aspiration precautions, adequate mouth care, and daily sedation vacations when applicable. Because researchers continue to evaluate ventilation strategies to benefit patients, clinicians must cautiously evaluate the results of case reports and animal research studies. Although no treatment strategy can be recommended at this time to reconcile permissive hypercarbia for brain injury with permissive hypercarbia for lung injury, individualized treatment decisions may incorporate data reviewed here when conventional treatment is not providing safe, effective care. The goal of the clinician must be to balance the current neurological and pulmonary guidelines to meet the needs of the individual to provide the best possible outcome. Wunsch, H., Mapstone, J., & Takala, J. (2005 Disclosure Statement:
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